← Eichor
Study identifier: NCT05018481 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

HA35 Moderate Alcoholic Hepatitis (AH) Study

Condition: Alcoholic Hepatitis  ·  Sponsor: The Cleveland Clinic

PhaseEARLY_Phase 1
Planned participants54
Who can joinAll sexes, 21 Years to 65 Years
Healthy volunteersNo

About this study

Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement administration. Both visits will include a physical exam, clinical labs, body composition measurements, muscle strength tests, questionnaires, and urine and stool collections. Additionally, a sugar cocktail will be consumed to measure gut permeability and a muscle biopsy will be collected. The day after the visits, you will need to return to drop off the 24-hour urine collection. Two phone visits will be performed in between the in-person visits at day 30 and 60 where you will be asked a series of questionnaires as well as asked about study supplement compliance.

This description comes directly from the study's public registry record.

Talk to the study team

Srinivasan Dasarathy, MD  ·  216-318-7010  ·  dasaras@ccf.org

Annette Bellar  ·  bellara@ccf.org

Always discuss trial participation with your own doctor first.

Locations (1)

Cleveland ClinicCleveland, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05018481